GH001 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant Depression
Conditions
Treatment-resistant Depression
Trial Timeline
May 24, 2023 → Mar 11, 2025
NCT ID
NCT05800860About GH001 + Placebo
GH001 + Placebo is a phase 2 stage product being developed by GH Research for Treatment-resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT05800860. Target conditions include Treatment-resistant Depression.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05800860 | Phase 2 | Completed |
Competing Products
6 competing products in Treatment-resistant Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 52 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 52 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 74 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 44 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 69 |